Printer Friendly

ORASCAN SHOWS 100% SENSITIVITY FOR ORAL CANCER IN NEW CLINICAL STUDY

 PHOENIX, Dec. 13 /PRNewswire/ -- Zila, Inc. (NASDAQ: ZILA), today announced that in London, results are in on a significant clinical study using OraScan(TM), the first oral cancer diagnostic aid. (OraScan's technology is backed by more than 100 clinical studies but this is the first study using the commercial kit.) Newell Johnson, Nuffield Professor of Dental Sciences at the Royal College of Surgeons, Kings College School of Medicine & Dentistry, used OraScan to test 102 patients at risk in Sri Lanka and Pakistan, where oral cancer is the No. 1 cause of cancer-related deaths. Patients were first given a routine visual examination; then the OraScan rinse sequence was used and a second examination was conducted to look for stained lesions. Professor Johnson's conclusions:
 1. All 11 carcinomas observed by the experts were successfully stained by OraScan.
 "All clinically suspected carcinomas stained deep blue with excellent marginal demarcation. -- The OraScan kit recognizes clinically apparent carcinomas with a 100% sensitivity. ... We conclude no false negative results were seen in carcinomas."
 2. OraScan stained an additional 12 lesions that had been overlooked by the experts. Upon further examination, five of these demonstrated microscopic dysplasia (a potentially pre-cancerous condition).
 "The five dysplastic lesions solely detected by the dye test suggest that the OraScan kit is valuable for surveillance of the oral cavity in high risk subjects in addition to its remarkable ability to have a high sensitivity in detection of invasive carcinomas."
 Professor Johnson is a world-renown authority on oral cancer and is a member of the U.K. Working Group on Oral Cancer & Precancer, an expert panel that is formulating a national policy on prevention, screening and treatment. His study is expected to be published in the near future.
 OraScan is proving highly accurate in the hands of dentists in general practice as well.
 In Sault Ste. Marie, Ontario, Dr. Harvey Snider, DDS, a general practitioner, has used OraScan successfully both for the identification of an asymptomatic cancerous lesion and for biopsy site selection. In one instance, he OraScan'd a patient of about 50 who is a smoker and drinker. A suspicious lesion in one area of the hard palate attracted the dentist's concern. With OraScan, that area did not stain (it was negative); but another area on the other side of the palate, which had gone unnoticed, did stain and was proven upon biopsy to be a very early stage squamous cell carcinoma of about 3x4 mm. In a second case, Dr. Snider was treating a patient who had already had surgery for oral cancer. According to Dr. Snider, "OraScan clearly stained an area at the periphery of the scar tissue, making it particularly easy for me to precisely communicate to the ear, nose and throat people the site of likely recurrence."
 "The success stories being generated in Canada and the impeccable clinical research findings coming from London and, soon, other research centers should make a very strong and positive impact on regulatory authorities and practitioners worldwide," said Zila President Joseph Hines. Zila recently announced it has established a U.S. manufacturing operation for the critical OraScan staining material, toluidine blue.
 OraScan was introduced in Canada last summer and is now beginning to find its way into widespread use by general practitioners there. The diagnostic aid has also been approved in Australia and is being reviewed by regulatory authorities in the United States and the United Kingdom.
 OraScan is a pre-measured, ready-to-use rinse sequence that stains abnormal lesions royal blue. Sold only to health professionals and typically administered during a routine dental check-up, the OraScan test takes only 5 minutes.
 Oral cancer is the eighth most common cancer type, but one of the deadliest -- owing to a history of late detection. Five-year survival rates are 18% for late-stage detection, 51% overall and 75% for early-stage detection. OraScan is so sensitive and accurate that cancerous lesions can be found before symptoms appear, significantly increasing the chance for cure.
 -0- 12/13/93
 /CONTACT: Joseph Hines of Zila, 602-266-6700/
 (ZILA)


CO: Zila, Inc. ST: Arizona IN: MTC SU:

TW -- NY014 -- 3026 12/13/93 09:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 13, 1993
Words:682
Previous Article:HERTZ REENTERS SOUTH AFRICA; SIGNS CAR RENTAL FRANCHISE AGREEMENT
Next Article:SURVEY REVEALS TOP SOURCES OF HOLIDAY STRESS FOR DETROIT RESIDENTS: EXPENSES, TIME, SHOPPING AND FAMILY OBLIGATIONS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters